argenx宣布管理层将参加9月两场投资者会议（Wells Fargo/Morgan Stanley）

这是一条标准的投资者会议参加公告，仅告知管理层将出席两场例行投资者大会，不包含任何新增业务事实、临床数据、监管进展、财务指引或战略变化，不构成可交易的事件催化。

📄 原文GlobeNewswire Biotechnology↗ 原文

argenx to Present at Upcoming Investor Conferences

September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company…

不做 argenx（ARGX.US）

例行投资者会议参加公告，不含任何新增事实、数据或指引，无方向性催化，无交易edge

展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

argenx于2026年9月1日通过GlobeNewswire发布例行公告，宣布管理层将参加9月8日Wells Fargo医疗健康会议和9月14日Morgan Stanley全球医疗健康会议。这是上市公司最常见的IR活动之一，不含任何新信息增量（无管线数据、无商业化进展、无指引变化、无监管里程碑），对市场预期无影响，不存在任何方向的交易edge。

🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗

先例如何影响了这次决策

对本次决策的影响:无需先例校准，事件本身不构成催化

方向:无适用先例

涨幅量级:无

形态:无

工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0

search_processed_events 成功 stock_tools HTTP · 235 ms
{"result": "search_processed_events:agent query=`argenx investor conference september 2026 | argenx morgan stanley global healthcare conference | argenx wells fargo healthcare conference`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.4/72 小时、1528 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件

原文全文

展开原文 · 1,561 字

September 1, 2026
Amsterdam, the Netherlands
– argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:
Wells Fargo 21st Annual Healthcare Conference
. Fireside chat on Tuesday, September 8, 2026 at 9:30 a.m. ET in Boston, MA.
Morgan Stanley 24th Annual Global Healthcare Conference
. Fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY.
A live webcast of the presentations may be accessed on the Investors section of the argenx website at
argenx.com/investors
. A replay of the webcasts will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit
www.argenx.com
and follow us on
LinkedIn
,
Instagram
,
Facebook
, and
YouTube
.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。